Binding Site
Analysis

Every protein-protein interaction involves two complementary surfaces: the epitope (the region on the target antigen recognized by the binder) and the paratope (the region on the binder that contacts the target). Understanding both surfaces is essential for rational design. Epitope mapping identifies which residues on the target are contacted by a binder, while paratope analysis reveals which residues on the binder contribute to recognition.

Experimental epitope mapping techniques include hydrogen-deuterium exchange mass spectrometry (HDX-MS), cross-linking mass spectrometry (XL-MS), alanine scanning mutagenesis, and peptide arrays. These methods vary in resolution and throughput—HDX-MS provides peptide-level resolution rapidly, while X-ray crystallography of the complex gives atomic-level detail but requires months of effort. Computationally, co-folding tools like Boltz-2 and AlphaFold-Multimer predict complex structures that reveal likely epitopes and paratopes, enabling binding site analysis before any experimental characterization is performed.

Not all residues at a binding interface contribute equally to binding affinity. Interface analysis decomposes the interaction into per-residue energy contributions, identifying which contacts are energetically favorable (hydrogen bonds, salt bridges, hydrophobic packing) and which are neutral or unfavorable (unsatisfied polar groups, steric strain). This decomposition guides engineering by highlighting positions where mutations could strengthen existing favorable contacts or eliminate unfavorable ones.

Shape complementarity scores, buried surface area calculations, and electrostatic surface analysis provide quantitative descriptors of interface quality. A high shape complementarity (Sc > 0.7) with substantial buried surface area (> 700 Å^2) generally indicates a well-packed interface. Gaps in packing or charge mismatches at the interface suggest specific positions where rational mutations could improve binding. For antibody engineering, this analysis often reveals that CDR3—the most variable loop—makes the dominant energetic contribution, while CDR1 and CDR2 provide supporting contacts that modulate specificity and orientation.

Not every surface on a protein is equally amenable to binding by a therapeutic molecule. Druggable sites tend to be concave, relatively hydrophobic, and biochemically important (involved in signaling, enzymatic activity, or protein-protein interactions). Computational pocket detection algorithms like P2Rank, FPocket, and SiteMap scan the protein surface for regions with favorable binding site geometry and chemistry.

For antibody and nanobody design, the target analysis extends beyond small-molecule pockets to consider the full protein surface. Flat, featureless surfaces are harder to target with high affinity because there are fewer geometric features for the paratope to grip. Conversely, targets with pronounced clefts, loops, or domain boundaries provide natural epitopes where binders can achieve high shape complementarity. Glycosylation sites, flexible regions, and membrane-proximal domains must also be considered, as these features can occlude potential epitopes or introduce steric barriers to binding in vivo.